Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Robbins Website

Paul F. Robbins, Ph.D.

Selected Publications

1)  Lanitis E, Smith JB, Dangaj D, Flingai S, Poussin M, Xu S, Czerniecki BJ, Li YF, Robbins PF, Powell DJ.
A human ErbB2-specific TCR confers potent anti-tumor effector functions in genetically engineered primary cytotoxic lymphocytes.
Hum. Gene Ther. [Epub ahead of print], 2014.
[Journal]
2)  Rosati SF, Parkhurst MR, Hong Y, Zheng Z, Feldman SA, Rao M, Abate-Daga D, Beard RE, Xu H, Black MA, Robbins PF, Schrump DA, Rosenberg SA, Morgan RA.
A novel murine T-cell receptor targeting NY-ESO-1.
J. Immunother. 37: 135-46, 2014.
[Journal]
3)  Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA.
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Science. 344: 641-5, 2014.
[Journal]
4)  Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, Robbins PF.
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.
Clin. Cancer Res. 20: 3401-10, 2014.
[Journal]
5)  Aung PP, Liu YC, Ballester LY, Robbins PF, Rosenberg SA, Lee CC.
Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma.
Hum. Pathol. 45: 259-67, 2014.
[Journal]
6)  Pos Z, Spivey TL, Liu H, Sommariva M, Chen J, Wunderlich JR, Parisi G, Tomei S, Ayotte BD, Stroncek DF, Malek JA, Robbins PF, Rivoltini L, Maio M, Chouchane L, Wang E, Marincola FM.
Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology.
J. Invest. Dermatol. 134: 1389-96, 2014.
[Journal]
7)  Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA.
PD-1 identifies the patient-specific CD8? tumor-reactive repertoire infiltrating human tumors.
J. Clin. Invest. 124: 2246-59, 2014.
[Journal]
8)  Turcotte S, Gros A, Tran E, Lee CC, Wunderlich JR, Robbins PF, Rosenberg SA.
Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.
Clin. Cancer Res. 20: 331-43, 2014.
[Journal]
9)  Feldman SA, Xu H, Black MA, Park TS, Robbins PF, Kochenderfer JN, Morgan RA, Rosenberg SA.
Use of the piggybac transponson to create stable packaging cell lines for the production clinical-grade self-inactivating ?-retroviral vectors.
Hum Gene Ther Methods. [Epub ahead of print], 2014.
[Journal]
10)  Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
J. Immunother. 36: 133-51, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 8/5/2014.